All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Momelotinib in MF: A real-world study of immune cell recovery
A real-world cohort study comparing the effects of momelotinib, a Janus kinase inhibitor, on immune cell recovery in ruxolitinib-treated and ruxolitinib-naïve patients with primary and secondary myelofibrosis (n = 46) vs healthy controls (n = 10) was published by Makker et al. in Haematologica.
Key data: T-cell subset frequencies increased by 6 weeks (CD3+: p = 0.01; CD4+: p = 0.03; and CD8+: p = 0.04) and remained elevated through 48 weeks (CD3+: p = 0.03; CD4+: p = 0.03; and CD8+: p = 0.13). Natural killer (NK) cells showed a three-fold increase from baseline to 48 weeks (p < 0.01), while B-cell counts were significantly higher at 6 weeks (p = 0.02) and 48 weeks (p = 0.04).
Key learning: Momelotinib demonstrated early and sustained recovery of T and NK cells, with levels comparable to healthy controls. These effects were observed irrespective of prior ruxolitinib exposure, highlighting momelotinib’s independent immunomodulatory activity.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
A 68-year-old male with primary myelofibrosis received ruxolitinib 10 mg twice daily for 7 months. His spleen size and symptoms are controlled, but Hb remains <8 g/dL. EPO, 210 mU/mL; platelets, 85,000/µL. What is your next step?
